Duvelisib(一种口服PI3K-δ/γ双重抑制剂)在惰性非霍奇金淋巴瘤的1期研究中显示临床活性
这项1期开放标签研究评估了口服PI3K-δ/γ双重抑制剂Duvelisib在晚期血液恶性肿瘤患者中的最大耐受剂量、药代动力学、药效动力学、临床活性和安全性。在31例可评估患者的剂量递增阶段,100 mg BID时出现2例剂量限制性毒性(3级转氨酶升高和3级皮疹),最大耐受剂量确定为75 mg BID。惰性非霍奇金淋巴瘤患者总缓解率为58.1%,中位缓解持续时间16.9个月,中位无进展生存期14.7个月。
要点
- 最大耐受剂量为75 mg BID,100 mg BID时出现2例剂量限制性毒性。
- 惰性非霍奇金淋巴瘤患者缓解率58.1%,中位缓解持续时间16.9个月。
- 3例致命不良事件均发生在75 mg BID队列。
核心结论
- Duvelisib在高危、重度经治的复发/难治性惰性非霍奇金淋巴瘤患者中显示出有利的临床活性和可接受的安全性特征,选择25 mg BID用于进一步临床开发。
研究设计与样本
- 1期开放标签研究,剂量递增阶段纳入31例可评估的晚期血液恶性肿瘤患者,Duvelisib按8个剂量水平(8-100 mg BID)口服给药。
主要发现
- 100 mg BID时出现2例剂量限制性毒性:3级转氨酶升高和3级皮疹;最大耐受剂量为75 mg BID。
- 所有剂量下,惰性非霍奇金淋巴瘤患者缓解率为58.1%(完全缓解19.4%,部分缓解35.5%,轻微缓解3.2%)。
- 中位至缓解时间1.84个月,中位缓解持续时间16.9个月,中位无进展生存期14.7个月,24个月总生存概率71.7%。
- 严重(≥3级)不良事件包括肝酶升高(38.7%)、腹泻(25.8%)和中性粒细胞减少(29.0%)。
- 3例致命不良事件均发生在75 mg BID队列:大肠埃希菌脓毒症、急性呼吸衰竭和真菌性肺炎;惰性非霍奇金淋巴瘤患者未发生肺孢子菌肺炎。
关键数值与推荐
- 最大耐受剂量为75 mg BID。
- 选择25 mg BID用于进一步临床开发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Duvelisib (IPI-145) is an oral dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ in clinical development for the treatment of hematologic malignancies, including indolent non-Hodgkin lymphoma (iNHL). In a Phase 1, open-label study to determine the maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, clinical activity, and safety of duvelisib monotherapy in patients with advanced hematologic malignancies, duvelisib was administered at eight dose levels (8-100 mg BID) in a dose-escalation phase (n = 31 evaluable patients). Two dose-limiting toxicities (DLTs), Grade 3 transaminase elevations and Grade 3 rash, occurred at 100 mg BID, and the MTD was determined to be 75 mg BID. Across all doses, 58.1% of iNHL patients had a response (19.4% complete, 35.5% partial, and 3.2% minor); median time to response was 1.84 months and duration of response was 16.9 months. Median progression-free survival was 14.7 months, and the probability of overall survival at 24 months was 71.7%. Severe (Grade ≥ 3) adverse events included elevated liver enzymes (38.7%), diarrhea (25.8%), and neutropenia (29.0%). Three patients, all in the 75 mg BID cohort, experienced fatal AEs: E. coli sepsis, acute respiratory failure, and fungal pneumonia. No iNHL patients experienced Pneumocystis pneumonia. Duvelisib demonstrated favorable clinical activity and an acceptable safety profile in these high-risk, heavily pretreated, relapsed/refractory iNHL patients, with 25 mg BID selected for further clinical development.
引用
- Flinn IW, Patel M, Oki Y, et al. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol. 2018. PMID: 30033575. doi:10.1002/ajh.25228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。